Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Aug 10

PMID 31394795

Citations 30

Authors

Eloi Franco-Trepat

Maria Guillan-Fresco

Ana Alonso-Perez

Alberto Jorge-Mora

Vera Francisco

Oreste Gualillo

Rodolfo Gomez

Affiliations

Soon will be listed here.

Abstract

Musculoskeletal pathologies (MSPs) such as osteoarthritis (OA) and osteoporosis (OP), are a set of disorders that cause severe pain, motion difficulties, and even permanent disability. In developed countries, the current incidence of MSPs reaches about one in four adults and keeps escalating as a consequence of aging and sedentarism. Interestingly, OA and OP have been closely related to similar risk factors, including aging, metabolic alterations, and inflammation. Visfatin, an adipokine with an inflammatory and catabolic profile, has been associated with several OA and OP metabolic risk factors, such as obesity, insulin resistance, and type II diabetes. Furthermore, visfatin has been associated with the innate immune receptor toll-like receptor 4 (TLR4), which plays a key role in cartilage and bone inflammatory and catabolic responses. Moreover, visfatin has been related to several OA and OP pathologic features. The aim of this work is to bring together basic and clinical data regarding the common role of visfatin in these pathologies and their major shared risk factors. Finally, we discuss the pitfalls of visfatin as a potential biomarker and therapeutic target in both pathologies.

Citing Articles

Anti-Aging Potential of Avocado Oil via Its Antioxidant Effects.

Torres-Isidro O, Gonzalez-Montoya M, Vargas-Vargas M, Florian-Rodriguez U, Garcia-Berumen C, Montoya-Perez R Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006059 PMC: 11858862. DOI: 10.3390/ph18020246.

Molecular Assessment of Plasma Concentrations of Selected Adipokines and IL-8 in Horses with Back Pain and Comorbid Asthma-Based on Clinical Cases.

Nowicka B, Polkowska I, Zeliszewska-Duk P, Torres A, Duk M Animals (Basel). 2025; 15(3).

PMID: 39943080 PMC: 11815831. DOI: 10.3390/ani15030310.

Visfatin Enhances RANKL-Induced Osteoclastogenesis In Vitro: Synergistic Interactions and Its Role as a Mediator in Osteoclast Differentiation and Activation.

Ok C, Kwon R, Jang H, Bae M, Bae S Biomolecules. 2025; 14(12.

PMID: 39766208 PMC: 11673010. DOI: 10.3390/biom14121500.

The Role of Adipokines between Genders in the Pathogenesis of Osteoarthritis.

Economou A, Mallia I, Fioravanti A, Gentileschi S, Nacci F, Bellando Randone S Int J Mol Sci. 2024; 25(19).

PMID: 39409194 PMC: 11476677. DOI: 10.3390/ijms251910865.

The role of obesity and adipose tissue dysfunction in osteoarthritis pain.

Binvignat M, Sellam J, Berenbaum F, Felson D Nat Rev Rheumatol. 2024; 20(9):565-584.

PMID: 39112603 DOI: 10.1038/s41584-024-01143-3.

References

Dobbs M, Buckwalter J, SALTZMAN C . Osteoporosis: the increasing role of the orthopaedist. Iowa Orthop J. 2000; 19:43-52. PMC: 1888612. View

Martin P, Shea R, Mulks M . Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol. 2001; 183(4):1168-74. PMC: 94989. DOI: 10.1128/JB.183.4.1168-1174.2001. View

Ognjanovic S, Bao S, Yamamoto S, Samal B, Bryant-Greenwood G . Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol. 2001; 26(2):107-17. DOI: 10.1677/jme.0.0260107. View

Gudbjornsson B, Juliusson U, Gudjonsson F . Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002; 61(1):32-6. PMC: 1753894. DOI: 10.1136/ard.61.1.32. View

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

Ognjanovic S, Bryant-Greenwood G . Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol. 2002; 187(4):1051-8. DOI: 10.1067/mob.2002.126295. View

Rongvaux A, Shea R, Mulks M, Gigot D, Urbain J, Leo O . Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2003; 32(11):3225-34. DOI: 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L. View

Kitani T, Okuno S, Fujisawa H . Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 2003; 544(1-3):74-8. DOI: 10.1016/s0014-5793(03)00476-9. View

Kanis J, Johansson H, Oden A, Johnell O, De Laet C, Melton Iii L . A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19(6):893-9. DOI: 10.1359/JBMR.040134. View

10.

Revollo J, Grimm A, Imai S . The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004; 279(49):50754-63. DOI: 10.1074/jbc.M408388200. View

11.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K . Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2004; 307(5708):426-30. DOI: 10.1126/science.1097243. View

12.

McGlothlin J, Gao L, Lavoie T, Simon B, Easley R, Ma S . Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet. 2005; 43(3-4):127-41. DOI: 10.1007/s10528-005-1505-2. View

13.

Borer K . Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors. Sports Med. 2005; 35(9):779-830. DOI: 10.2165/00007256-200535090-00004. View

14.

Ye S, Zhang L, Adyshev D, Usatyuk P, Garcia A, Lavoie T . Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res. 2005; 70(3):142-51. DOI: 10.1016/j.mvr.2005.08.003. View

15.

Chen M, Chung F, Chang D, Tsai J, Huang H, Shin S . Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005; 91(1):295-9. DOI: 10.1210/jc.2005-1475. View

16.

Ginaldi L, Di Benedetto M, De Martinis M . Osteoporosis, inflammation and ageing. Immun Ageing. 2005; 2:14. PMC: 1308846. DOI: 10.1186/1742-4933-2-14. View

17.

Curat C, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R . Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006; 49(4):744-7. DOI: 10.1007/s00125-006-0173-z. View

18.

Aksoy P, White T, Thompson M, Chini E . Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006; 345(4):1386-92. DOI: 10.1016/j.bbrc.2006.05.042. View

19.

Wang T, Zhang X, Bheda P, Revollo J, Imai S, Wolberger C . Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006; 13(7):661-2. DOI: 10.1038/nsmb1114. View

20.

Khan J, Tao X, Tong L . Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006; 13(7):582-8. DOI: 10.1038/nsmb1105. View